BCI
LGND icon

Brinker Capital Investments’s Ligand Pharmaceuticals LGND Stock Holding History

Brinker Capital Investments’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$642K Sell
3,217
-284
-8% -$56.2K 0.01% 1351
2025
Q4 		$662K Buy
3,501
+2,315
+195% +$445K ﹤0.01% 1461
2025
Q3 		$210K Buy
+1,186
New +$176K ﹤0.01% 1949
2022
Q1 		– Sell
-2,092
Closed -$202K – 1402
2021
Q4 		$202K Buy
+2,092
New +$193K ﹤0.01% 1351

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Brinker Capital Investments's LGND Position: Q1 2026 in Review

Brinker Capital Investments reduced its Ligand Pharmaceuticals (LGND) stake by 8.1% in Q1 2026, selling an estimated $56.2K and leaving 3,217 shares worth $642K. The position accounts for 0.01% of the portfolio, ranked #1351.

Brinker Capital Investments first reported a position in LGND in Q4 2021 and has held it in 4 quarters since. The position peaked at $662K in Q4 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Brinker Capital Investments held 3,217 shares of Ligand Pharmaceuticals worth $642K as of Q1 2026.
  • Brinker Capital Investments sold 284 Ligand Pharmaceuticals shares in Q1 2026, an estimated $56.2K.
  • Ligand Pharmaceuticals made up 0.01% of Brinker Capital Investments's portfolio in Q1 2026, its #1351 holding.
  • Brinker Capital Investments first reported a position in Ligand Pharmaceuticals in Q4 2021 and has held it in 4 quarters since.
  • Brinker Capital Investments's Ligand Pharmaceuticals position peaked at $662K in Q4 2025.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Brinker Capital Investments's 13F filing for Q1 2026, filed 13 May 2026.